Work

Supplementary Figure 3 from Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 399KB, Supplemental Figure 3. SCLC PDXs and cell lines express mTOR pathway components and the combination of ABT-737 and rapamycin is well tolerated in PDX-bearing mice.

DOI: 10.1158/0008-5472.22403946.v1

Authors: Eric E. Gardner, Nick Connis, John T. Poirier, Leslie Cope, Irina Dobromilskaya, Gary L. Gallia, Charles M. Rudin, Christine L. Hann

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361848609

Cites:

Cited by:

Related to: 10